Ypsomed: Medtech Company Establishes First Production Site in the USA

The new production site in Holly Springs in the state of North Carolina - (Image: Ypsomed).

The medtech company Ypsomed plans to establish a new production site in Holly Springs, Wake County, North Carolina. It is the Swiss company's first manufacturing facility in the United States. In the first phase of expansion, Ypsomed is investing approximately 200 million Swiss francs in the new facility, according to its own statements. Production is scheduled to start at the end of 2027.

With the Holly Springs location, Ypsomed pursues the goal of strengthening the supply chain for the North American market, expanding proximity to existing and potential customers, and locally serving the growing demand for injection systems for self-medication. The new facility is initially expected to create around 100 jobs, with a mid-term expansion to up to 200 employees planned, dependent on market development.

Advert

Ypsomed is acquiring an existing industrial building with an area of approximately 15,000 square meters. The building offers expansion potential to further increase capacity in the future. The new US location complements Ypsomed's existing production network and is seen as part of a global expansion strategy aimed at increasing capacity and supply chain resilience.

The decision for Holly Springs was made, among other things, due to the existing biopharmaceutical infrastructure in North Carolina's "Research Triangle," which is home to over 650 life sciences companies. The proximity to research institutions and qualified specialist personnel played a central role in the site selection.

Parallel to setting up the US production site, Ypsomed is also implementing growth initiatives in other regions. This year, the company commissioned its first own plant in Changzhou, China, and initiated the expansion of the "Schwerin 2" production site in Germany. In Switzerland, the Solothurn site is being expanded with an investment of approximately 200 million francs. The corresponding construction work has already started.

Ypsomed, headquartered in Burgdorf, Switzerland, specializes in the development and production of injection systems for the self-administration of liquid medications and operates a global network of manufacturing sites.

More information: www.ypsomed.com

Ypsomed AG, Burgdorf, Switzerland

back to news list